Ameriprise
LCTX icon

Ameriprise’s Lineage Cell Therapeutics LCTX Stock Holding History

Ameriprise’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,500
Closed -$21.3K – 4130
2025
Q2 		$21.3K Sell
23,500
-23,397
-50% -$13.9K ﹤0.01% 3939
2025
Q1 		$21.2K Buy
46,897
+4,019
+9% +$2.36K ﹤0.01% 3980
2024
Q4 		$21.5K Buy
42,878
+19,378
+82% +$14.2K ﹤0.01% 4046
2024
Q3 		$21.3K Sell
23,500
-160
-0.7% -$148 ﹤0.01% 3906
2024
Q2 		$23.6K Hold
23,660
– – ﹤0.01% 3837
2024
Q1 		$35K Sell
23,660
-2,000
-8% -$2.27K ﹤0.01% 3821
2023
Q4 		$28K Hold
25,660
– – ﹤0.01% 3866
2023
Q3 		$30.3K Sell
25,660
-14
-0.1% -$19 ﹤0.01% 3856
2023
Q2 		$36.2K Hold
25,674
– – ﹤0.01% 3877
2023
Q1 		$38.5K Buy
25,674
+14
+0.1% +$20 ﹤0.01% 3881
2022
Q4 		$30K Sell
25,660
-43,600
-63% -$54.9K ﹤0.01% 3881
2022
Q3 		$78K Buy
69,260
+28,600
+70% +$42K ﹤0.01% 3862
2022
Q2 		$64K Buy
+40,660
New +$53.6K ﹤0.01% 3816
2022
Q1 		– Sell
-304,989
Closed -$747K – 3991
2021
Q4 		$747K Buy
+304,989
New +$714K ﹤0.01% 3381
2018
Q3 		– Sell
-42,973
Closed -$78K – 3755
2018
Q2 		$78K Sell
42,973
-30,939
-42% -$62.3K ﹤0.01% 3583
2018
Q1 		$172K Buy
73,912
+3,469
+5% +$8.13K ﹤0.01% 3506
2017
Q4 		$133K Sell
70,443
-1,955
-3% -$4.27K ﹤0.01% 3536
2017
Q3 		$180K Buy
72,398
+20,637
+40% +$51.2K ﹤0.01% 3534
2017
Q2 		$142K Buy
+51,761
New +$145K ﹤0.01% 3620
2014
Q4 		– Sell
-9,280
Closed -$24K – 4088
2014
Q3 		$24K Buy
9,280
+8,896
+2,317% +$21.4K ﹤0.01% 4394
2014
Q2 		$1K Buy
+384
New +$867 ﹤0.01% 5352
2013
Q4 		– Sell
-2,852
Closed -$9K – 5300
2013
Q3 		$9K Hold
2,852
– – ﹤0.01% 4976
2013
Q2 		$9K Buy
+2,852
New +$9.14K ﹤0.01% 4856

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's LCTX Position: Q3 2025 in Review

Ameriprise sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 23,500 shares — an estimated $21.3K sold.

Ameriprise first reported a position in LCTX in Q2 2013 and held it in 23 quarters. The position peaked at $747K in Q4 2021. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Ameriprise reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ameriprise sold 23,500 Lineage Cell Therapeutics shares in Q3 2025, an estimated $21.3K.
  • Ameriprise first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 23 quarters.
  • Ameriprise's Lineage Cell Therapeutics position peaked at $747K in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.